You are here

Inflammation and Immunology Areas of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected].

Question Pairs: 
Question: 

Atopic Dermatitis (Crisaborole)

Answer: 
Research areas to be considered for Pfizer support include:
  • Patterns of usage of topical therapies, including frequency, duration and continuity of use
  • Defining AD “flare” and the severity of AD, including with commonly used scales
  • Studies that define optimal medical management of atopic dermatitis, including adherence to topical therapy, and consequences of suboptimal management 
  • Studies to explore and define the chronic systemic burden of illness 
  • Assessment and impact of emotional burden related to atopic dermatitis
  • Progression to chronic or more severe forms of AD
  • Early and long term treatment to normalize skin barrier/immune function
  • Characterization and impact of co-morbidities and the atopic march 
  • Understanding burden and real world management of atopic itch and skin pain 
  • Prediction of response to treatment
  • Reduction in the use of other topical therapies and/or adjunctive therapy
  • Reduction in healthcare resource utilization
Question: 

Inflammatory Conditions

Answer: 
Research areas to be considered for Pfizer support include:
  • Assessment of patients who switch agents during their treatment
  • Prediction of response to treatment 
  • Evaluation of special populations
  • Characterization of the mechanistic basis and durability of monotherapy
  • Non-clinical examination of the relative efficacy/specificity of JAK inhibitors
  • Studies to investigate the mechanistic basis of herpes zoster risk
  • Evaluations of the impact of value-added-services on PROs and adherence
  • Impact of diet on disease
Question: 

Gastroenterology

Answer: 
Research areas to be considered for Pfizer support include:
  • Evaluation of biomarkers as predictors of efficacy in UC
  • Evaluation of lipid elevations observed in UC patients
  • Evaluation of the ability to restart therapy after interruption in UC patients
Question: 

Spondyloarthritis (SpA)

Answer: 
Research areas to be considered for Pfizer support include:
  • Studies of unmet medical need/disease burden in SpA/PsA/AS (e.g., early diagnosis tools, oral dosing/patient preference, adherence)
  • Examination of real-world data
  • Efficacy measurements for SpA/PsA/AS clinical research
  • Characterization of how appropriate treatment reduces disease activity in the core domains of psoriatic arthritis with a focus on skin, enthesitis, dactylitis, and axial disease
  • Characterization of how JAK inhibitors inhibit structural progression
Question: 

Innovative Research in Inflammatory Conditions

Answer: 

Pfizer is also interested in supporting innovative research in other inflammatory conditions, some areas or examples include: Systemic Lupus Erythema, Vasculitis, Vitiligo, and Alopecia Areata.